Analyzing...
Loading company...
Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. The company is headquartered in Ahmedabad, Gujarat and currently employs 23,026 full-time employees. The firm is engaged in the research and development, manufacturing, marketing and selling of finished dosage human formulations, such as generics and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients (APIs); animal healthcare products, and consumer wellness products. Its products include Bilypsa (saroglitizar), Oxemia (desidustat), Ujvira (biosimilar Kadcyla), and Exemptia. The company offers Bilypsa drug for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Desidustat is an oral, small molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, which is used for the treatment of anemia in chronic kidney disease (CKD) patients. The company is also developing an oral small molecule ZYIL1, targeted at selectively suppressing inflammation caused by the NLRP3 inflammasome. Its ZyCoV-D is a plasmid deoxyribonucleic acid (DNA) vaccine for COVID-19.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹27,148 Cr revenue.
COGS 26.9%, employees 16.3%.
“We are on track to achieve our targeted top line growth and profitability for the current financial year”
“Our guidance is intact for the year...maintain 26% plus margin for this entire year”
“Net debt to EBITDA ratio, without any question, we don't want to cross one time. For a short period, we can go two times”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 18.6%▲ | 10.3% |
| ROCE | 19.2%▲ | 13.7% |
| Net Margin | 18.2%▲ | 7.6% |
| EBITDA Margin | 30.6%▲ | 15.4% |
| Debt To Equity | 0.43x▲ | 0.15x |
| Rev Growth 3yr | 16.7%▲ | 10.0% |
| EPS Growth 3yr | 37.3%▲ | 16.0% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹27,148 Cr +16.8% | ₹23,242 Cr +18.9% | ₹19,547 Cr +13.4% | ₹17,237 Cr +12.9% | ₹15,265 Cr +1.1% | ₹15,102 Cr +6.0% | ₹14,253 Cr +8.3% | ₹13,166 Cr |
| Other Income | ₹510 Cr +89.1% | ₹270 Cr -5.1% | ₹284 Cr +52.3% | ₹187 Cr -17.0% | ₹225 Cr +504.0% | ₹37 Cr -67.3% | ₹114 Cr -43.4% | ₹201 Cr |
| Total Income | ₹27,658 Cr +17.6% | ₹23,511 Cr +18.6% | ₹19,832 Cr +13.8% | ₹17,424 Cr +12.5% | ₹15,490 Cr +2.3% | ₹15,139 Cr +5.4% | ₹14,367 Cr +7.5% | ₹13,367 Cr |
| COGS | ₹7,293 Cr +15.1% | ₹6,338 Cr +1.8% | ₹6,228 Cr -1.3% | ₹6,310 Cr +13.8% | ₹5,545 Cr +6.4% | ₹5,210 Cr +5.9% | ₹4,920 Cr +4.3% | ₹4,716 Cr |
| ₹20,520 Cr +18.9% | ₹17,265 Cr +15.0% | ₹15,008 Cr +5.5% | ₹14,230 Cr +11.5% | ₹12,765 Cr +0.9% | ₹12,650 Cr +1.1% | ₹12,508 Cr +13.9% | ₹10,985 Cr | |
| Profit Before Tax | ₹6,621 Cr +9.9% | ₹6,027 Cr +25.3% | ₹4,809 Cr +85.7% | ₹2,590 Cr -8.8% | ₹2,838 Cr +24.2% | ₹2,285 Cr +52.8% | ₹1,495 Cr -37.2% | ₹2,382 Cr |
| Exceptional Items | (₹517 Cr) -135.2% | (₹220 Cr) | (₹14 Cr) +97.6% | (₹604 Cr) ↓ Decline | ₹113 Cr ↑ Recovery | (₹205 Cr) +43.6% | (₹364 Cr) | ₹0.00 Cr |
| ₹1,595 Cr +12.9% | ₹1,412 Cr +44.4% | ₹978 Cr +66.3% | ₹588 Cr +14.9% | ₹512 Cr +247.6% | ₹147 Cr -54.0% | ₹320 Cr -39.7% | ₹530 Cr | |
| Net Profit | ₹5,124 Cr +9.6% | ₹4,673 Cr +17.6% | ₹3,973 Cr +89.9% | ₹2,092 Cr -54.7% | ₹4,618 Cr +111.4% | ₹2,185 Cr +81.4% | ₹1,204 Cr -36.6% | ₹1,899 Cr |
| Profit (Owners) | ₹5,040 Cr | ₹147 Cr +29.8% | ₹113 Cr -94.2% | ₹1,960 Cr -56.3% | ₹4,487 Cr +110.3% | ₹2,134 Cr +81.3% | ₹1,177 Cr -36.4% | ₹1,849 Cr |
| Minority Interest | ₹84 Cr -98.2% | ₹4,526 Cr +17.3% | ₹3,860 Cr | ₹132 Cr +0.5% | ₹131 Cr +154.9% | ₹51 Cr +84.9% | ₹28 Cr -44.3% | ₹50 Cr |
| Other Comprehensive Income | (₹775 Cr) -674.8% | (₹100 Cr) +50.0% | (₹200 Cr) +36.4% | (₹314 Cr) -200.9% | (₹105 Cr) ↓ Decline | ₹73 Cr ↑ Recovery | (₹301 Cr) -78.9% | (₹168 Cr) |
| EPS | ₹50.10 | ₹1.46 | ₹1.13 | ₹19.37 | ₹43.83 | ₹20.84 | ₹11.49 | ₹18.06 |
| Diluted Shares | ₹101 Cr | ₹101 Cr | ₹101 Cr | ₹101 Cr | ₹102 Cr | ₹102 Cr | ₹102 Cr | ₹102 Cr |
| Profit Or Loss Of Associates | ₹97 Cr +68.0% | ₹58 Cr -51.2% | ₹118 Cr +25.2% | ₹95 Cr +104.8% | ₹46 Cr -2.5% | ₹47 Cr +64.6% | ₹29 Cr -38.6% | ₹47 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Zydus Lifesciences Limited has informed the Exchange about Schedule of meet
Zydus Lifesciences Limited has informed the Exchange about General Updates
Zydus Lifesciences Limited has informed the Exchange about Disruption of Operations
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 23, 2026, titled "Zydus receives approval for Phase III trial of Desidustat in patients with Sickle Cell Disea...
The Exchange has sought clarification from Zydus Lifesciences Limited with respect to recent news item captioned Delhi HC Temporarily Restricts Supply Of Zydus Cancer Drug Ikra In AbbVie Patent Disput...
The Exchange has sought clarification from Zydus Lifesciences Limited with respect to recent news item captioned Delhi HC Temporarily Restricts Supply Of Zydus Cancer Drug Ikra In AbbVie Patent Disput...
Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication
Zydus Lifesciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 11, 2026
Zydus Lifesciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Zydus Lifesciences Limited has informed the Exchange about General Updates
Zydus Lifesciences Limited has informed the Exchange regarding 'Disclosures under Insider Trading Regulations'.
Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated Jun 16, 2026, titled "Zydus announces the successful completion of acquisition of Assertio Holdings".
Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication
Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication